The Journal of Practical Medicine >
Analysis of the expression of lymphoid enhancer binding factor 1 in B cell chronic lymphoproliferative disorders
Received date: 2023-08-22
Online published: 2024-04-08
Objective To investigate the expression of lymphoid enhancer binding factor 1 （LEF1） in B cell chronic lymphoproliferative disorders （B?CLPD） and estimate its value in the differential diagnosis of the subtype of B?CLPD. Methods A retrospective study was conducted on 58 patients diagnosed with B?CLPD by using bone marrow biopsy samples or lymphnode biopsy samples from Hematology Department of The Second People's Hospital of Wuhu from September 2018 to June 2023， as well as 20 bone marrow biopsy samples which were diagnosis as non?hematologic malignancy in the control group. Immunohistochemical method was used to detect the expression of LEF1 in 78 samples， and statistical analysis was conducted. Results In all 78 cases， 16 of 20 chronic lymphocytic leukemia （CLL） patients were LEF1 positive， the positive rate was 80%； mantle cell lymphoma 1/12； Follicular lymphoma 1/5； marginal zone cell lymphoma 0/11； Lymphoplasmacyticlymphom 0/8； hairy cell leukemia 0/2； in Control group no patient was LEF1 positive（P = 0.000）. The expression of LEF1 is correlated with CD200 and CLL score（P < 0.05）. In the LEF1 negative group with 4 CLL patients， 2 were detected with +12 chromosomal abnormality， the detective rate was higher than that of the LEF1 positive group（P > 0.05）. Conclusion LEF1 was a sensitive and specific diagnosis marker in CLL and B?CLPD subtype.
Min ZHAO , Ping NI , Huiying ZHAI , Xiaoke JIN , Yuqiong. YANG . Analysis of the expression of lymphoid enhancer binding factor 1 in B cell chronic lymphoproliferative disorders[J]. The Journal of Practical Medicine, 2024 , 40(7) : 984 -988 . DOI: 10.3969/j.issn.1006-5725.2024.07.018
| 1 | 中华医学会血液学分会、中国抗癌协会血液肿瘤专业委员会 ．中国B细胞慢性淋巴增殖性疾病诊断专家共识（2014年版）［J］. 中华血液学杂志， 2014， 35（4）：367-370. |
| 2 | 中华医学会血液学分会白血病淋巴瘤学组， 中国抗癌协会血液肿瘤专业委员会， 中国慢性淋巴细胞白血病工作组. 中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的诊断与治疗指南（2018年版）［J］. 中华血液学杂志， 2018， 39（5）： 353-358. doi:10.3760/cma.j.issn.0253-2727.2018.05.001 |
| 3 | QI Y， SHAN Y， LI S， et al. LncRNA LEF1-AS1/LEF1/FUT8 Axis Mediates Colorectal Cancer Progression by Regulating α1， 6-Fucosylationvia Wnt/β-Catenin Pathway［J］. Dig Dis Sci， 2022，67（6）：2182-2194. doi:10.1007/s10620-021-07051-w |
| 4 | CHEN D， LI K， PAN L， et al. TCF7 and LEF-1 downregulation in sepsis promotes immune suppression by inhibiting CD4+ T cell proliferation［J］. Microb Pathog， 2023，184：106362. doi:10.1016/j.micpath.2023.106362 |
| 5 | SWERDLOW S H， CAMP E， HARRIS N L，et al. WHO classification of tumours of haematopoietic and lymphoid tissues［M］.4th ed. Lyon： IARC Press， 2017. |
| 6 | SORIGUE M， JURADO R. Flow cytometry in leukaemic B cell lymphoproliferative disorders. New scores， same old concerns［J］. Int J Lab Hematol， 2022，44（6）：e262-e264. doi:10.1111/ijlh.13922 |
| 7 | 王巍，刘文鑫，黄永彬，等， 急性白血病β-catenin与LEF 1基因表达的相关性［J］. 实用医学杂志， 2018，34（12）：1986-1989. |
| 8 | GU S， LIU F， XIE X，et al. β-Sitosterol blocks the LEF-1-mediated Wnt/β-catenin pathway to inhibit proliferation of human colon cancer cells［J］. Cell Signal， 2023，104：110585. doi:10.1016/j.cellsig.2022.110585 |
| 9 | SANTIAGO L， DANIELS G， WANG D， et al. Wnt signaling pathway protein LEF1 in cancer， as a biomarker for prognosis and a target for treatment［J］. Am J Cancer Res， 2017，7（6）：1389-1406. |
| 10 | CARR T， MCGREGOR S， DIAS S， et al. Oncogenic and Tumor Suppressor Functions for Lymphoid Enhancer Factor 1 in E2a-/- T Acute Lymphoblastic Leukemia［J］. Front Immunol， 2022，18（13）：845488. |
| 11 | 陈雪，芮炜炜，毕珂，等. 淋巴样增强结核因子1蛋白表达在淋巴母细胞淋巴瘤/急性淋巴细胞白血病中的诊断及鉴别诊断研究［J］. 中华病理学杂志， 2021，50（3）：207-212. |
| 12 | MENTER T， TRIVEDI P， AHMAD R， et al. Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas［J］. Am J ClinPathol， 2017，147（3）：292-300. |
| 13 | RAVINDRAN A， KURTIN P J， KING R L，et al. Aberrant expression of lymphoid enhancer-binding factor 1 in Hodgkin lymphoma［J］. Hum Pathol， 2022，125：2-10. doi:10.1016/j.humpath.2022.04.004 |
| 14 | O'MALLEY D P， LEE J P， BELLIZZI A M. Expression of LEF1 in mantle cell lymphoma［J］. Ann Diagn Pathol， 2017，26：57-59. doi:10.1016/j.anndiagpath.2016.09.016 |
| 15 | MENTER T， DIRNHOFER S， TZANKOV A. LEF1： a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma［J］. J Clin Pathol，2015，68（6）：473-478. doi:10.1136/jclinpath-2015-202862 |
| 16 | RANGAN A， REINIG E， MCPHAIL E D， et al. Immunohistochemistry for LEF1 and SOX11 adds diagnostic specificity in small B-cell lymphomas［J］. Hum Pathol， 2022，121：29-35. doi:10.1016/j.humpath.2022.01.001 |
| 17 | AL-ZUBAIDI H K， HUGHES S F. The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders［J］. Br J Biomed Sci， 2023，26（80）：11573. |
| 18 | KOHNKE T， WITTMANN V K， BüCKLEIN V L，et al. Diagnosis of CLL revisited： increased specificity by a modified five-marker scoring system including CD200［J］. Br J Haematol，2017，179（3）：480-487. doi:10.1111/bjh.14901 |
| 19 | REA B， BAILEY N G. Additional characterization of LEF1 expression in nodular lymphocyte predominant Hodgkin lymphoma and classic Hodgkin lymphoma［J］. Ann Diagn Pathol， 2021，52：151730. doi:10.1016/j.anndiagpath.2021.151730 |
| 20 | SOLIMAN D S， AL-KUWARI E， SIVEEN K S， et al. Downregulation of Lymphoid enhancer-binding factor 1 （LEF-1） expression （by immunohistochemistry and/flow cytometry） in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features［J］. Int J Lab Hematol， 2021，43（3）：515-525. doi:10.1111/ijlh.13420 |
| 21 | PATEL N， DURKIN L， BODO J， et al. Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone， Lymphoplasmacytic， and Follicular Lymphomas［J］. Am J Clin Pathol， 2020，153 （5）：646-655. doi:10.1093/ajcp/aqz207 |
| 22 | MOLLSTEDT J， MANSOURI L， ROSENQUIST R. Precision diagnostics in chronic lymphocytic leukemia： Past， present and future［J］. Front Oncol， 2023，21 （13）：1146486 . |
/
| 〈 |
|
〉 |